Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

November 12, 2018
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans

November 1, 2018
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy

October 29, 2018
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience

September 25, 2018
Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference

September 14, 2018
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain

See all press and news »